Korsana Biosciences

Executive Summary

Korsana Biosciences is a private San Diego-based biotechnology company founded in 2021, dedicated to developing novel therapeutics for neurodegenerative diseases, with an initial focus on Alzheimer's disease. The company's core innovation is the THETA™ blood-brain barrier (BBB) shuttle platform, which enables efficient delivery of large-molecule biologics to the central nervous system. This platform addresses a critical hurdle in neurodegenerative disease treatment, as the BBB typically restricts the passage of therapeutic antibodies and proteins. Korsana's approach leverages proprietary technology to facilitate transcytosis, potentially unlocking a new class of biologics for Alzheimer's and other CNS disorders. As an early-stage company, Korsana is currently in preclinical development, aiming to advance its lead candidates toward clinical trials. The company has not publicly disclosed financing rounds or valuation, but its differentiated platform positions it as a potential player in the competitive Alzheimer's landscape. Success will depend on preclinical validation, regulatory progress, and ability to secure partnerships or funding to support IND-enabling studies and eventual clinical development.

Upcoming Catalysts (preview)

• TBDPreclinical Proof-of-Concept Data in Alzheimer's Models60% success
• TBDIND Filing for Lead Candidate40% success
• TBDPartnership or Licensing Deal for THETA Platform50% success